{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:19:46Z","timestamp":1789193986458,"version":"build-2803163510"},"reference-count":159,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["2021-PT320-002"],"award-info":[{"award-number":["2021-PT320-002"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","award":["2022YFC2504600"],"award-info":[{"award-number":["2022YFC2504600"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["2022-I2M-1-004"],"award-info":[{"award-number":["2022-I2M-1-004"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["2021-I2M-1-005"],"award-info":[{"award-number":["2021-I2M-1-005"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["2023-I2M-2-005"],"award-info":[{"award-number":["2023-I2M-2-005"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.drudis.2025.104554","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T02:52:17Z","timestamp":1763693537000},"page":"104554","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Advances and challenges in Toll-like receptor-targeted therapy for rheumatoid arthritis"],"prefix":"10.1016","volume":"31","author":[{"given":"Xin-yuan","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-ning","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2504-1629","authenticated-orcid":false,"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2025.104554_b0005","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJMra2103726","article-title":"Rheumatoid arthritis \u2013 common origins, divergent mechanisms","volume":"388","author":"Gravallese","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2025.104554_b0010","doi-asserted-by":"crossref","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.drudis.2025.104554_b0015","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/s41584-023-01035-y","article-title":"Rheumatoid arthritis prevention in arthralgia: fantasy or reality?","volume":"19","author":"van Steenbergen","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.drudis.2025.104554_b0020","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1515\/rir-2024-0026","article-title":"Enhancing standardized diagnosis and treatment to improve the prognosis of patients with rheumatoid arthritis in China","volume":"5","author":"Jiang","year":"2024","journal-title":"Rheumatol Immunol Res"},{"key":"10.1016\/j.drudis.2025.104554_b0025","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.drudis.2025.104554_b0030","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/1478-6354-13-S1-S5","article-title":"Advances in rheumatology: new targeted therapeutics","volume":"13","author":"Tak","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.drudis.2025.104554_b0035","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1146\/annurev-pathmechdis-012419-032847","article-title":"DAMPs, PAMPs, and LAMPs in immunity and sterile inflammation","volume":"15","author":"Zindel","year":"2020","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.drudis.2025.104554_b0040","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.cell.2020.02.041","article-title":"Toll-like receptors and the control of immunity","volume":"180","author":"Fitzgerald","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2025.104554_b0045","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1146\/annurev-immunol-101721-031732","article-title":"Effector-triggered immunity","volume":"41","author":"Remick","year":"2023","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.drudis.2025.104554_b0050","doi-asserted-by":"crossref","first-page":"13397","DOI":"10.3390\/ijms222413397","article-title":"Toll-like receptors (TLRs), NOD-like receptors (NLRs), and RIG-I-like receptors (RLRs) in innate immunity. TLRs, NLRs, and RLRs ligands as immunotherapeutic agents for hematopoietic diseases","volume":"22","author":"Wicherska-Paw\u0142owska","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104554_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2024.102460","article-title":"Rethinking Toll-like receptor signalling","volume":"91","author":"Bryant","year":"2024","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.drudis.2025.104554_b0060","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/ni.1863","article-title":"The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors","volume":"11","author":"Kawai","year":"2010","journal-title":"Nat Immunol"},{"key":"10.1016\/j.drudis.2025.104554_b0065","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.812774","article-title":"Toll-like receptor signaling and its role in cell-mediated immunity","volume":"13","author":"Duan","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2025.104554_b0070","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1136\/annrheumdis-2012-202444","article-title":"Hypoxia and hypoxia-inducible factor-1\u03b1 provoke toll-like receptor signalling-induced inflammation in rheumatoid arthritis","volume":"73","author":"Hu","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.drudis.2025.104554_b0075","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nrrheum.2016.61","article-title":"Toll-like receptors and chronic inflammation in rheumatic diseases: new developments","volume":"12","author":"Joosten","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.drudis.2025.104554_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.autrev.2015.08.009","article-title":"The critical role of toll-like receptors\u2014from microbial recognition to autoimmunity: a comprehensive review","volume":"15","author":"Jim\u00e9nez-Dalmaroni","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.drudis.2025.104554_b0085","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nrd3203","article-title":"Targeting Toll-like receptors: emerging therapeutics?","volume":"9","author":"Hennessy","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2025.104554_b0090","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/9914854","article-title":"Toll-like receptors: general molecular and structural biology","volume":"2021","author":"Behzadi","year":"2021","journal-title":"J Immunol Res"},{"key":"10.1016\/j.drudis.2025.104554_b0095","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/jdv.12130","article-title":"Comparison of cytokine gene polymorphism in drug-induced maculopapular eruption, urticaria and drug reaction with eosinophilia and systemic symptoms (DRESS)","volume":"28","author":"Barbaud","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.drudis.2025.104554_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.137836","article-title":"The dual role of toll-like receptors in COVID-19: balancing protective immunity and immunopathogenesis","volume":"284","author":"Behzadi","year":"2025","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.drudis.2025.104554_b0105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1294869","article-title":"Editorial: the innate and adaptive immune system in human urinary system","volume":"14","author":"Behzadi","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2025.104554_b0110","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1244345","article-title":"Toll-like receptor-guided therapeutic intervention of human cancers: molecular and immunological perspectives","volume":"14","author":"Mukherjee","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2025.104554_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102597","article-title":"TLR expression profiles are a function of disease status in rheumatoid arthritis and experimental arthritis","volume":"118","author":"Clanchy","year":"2021","journal-title":"J Autoimmun"},{"key":"10.1016\/j.drudis.2025.104554_b0120","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s12016-019-08742-z","article-title":"Toll-like receptors, infections, and rheumatoid arthritis","volume":"58","author":"Arleevskaya","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.drudis.2025.104554_b0125","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13075-015-0664-8","article-title":"Toll-like receptor 2 (TLR2) induces migration and invasive mechanisms in rheumatoid arthritis","volume":"17","author":"McGarry","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.drudis.2025.104554_b0130","article-title":"The expression of inflammasomes NLRP1 and NLRP3, toll-like receptors, and vitamin D receptor in synovial fibroblasts from patients with different types of knee arthritis","volume":"12","author":"Sakalyte","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2025.104554_b0135","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1136\/annrheumdis-2011-200899","article-title":"SNAPIN: an endogenous Toll-like receptor ligand in rheumatoid arthritis","volume":"71","author":"Shi","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.drudis.2025.104554_b0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-015-8473-z","article-title":"Toll-like receptor pathways in autoimmune diseases","volume":"50","author":"Chen","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.drudis.2025.104554_b0145","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00296-013-2666-7","article-title":"Toll-like receptor polymorphisms and rheumatoid arthritis: a systematic review","volume":"34","author":"Lee","year":"2014","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.drudis.2025.104554_b0150","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12969-017-0137-5","article-title":"TLR4 rs41426344 increases susceptibility of rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) in a central south Chinese Han population","volume":"15","author":"Wang","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.drudis.2025.104554_b0155","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/ni.2284","article-title":"Genetic variation in Toll-like receptors and disease susceptibility","volume":"13","author":"Netea","year":"2012","journal-title":"Nat Immunol"},{"key":"10.1016\/j.drudis.2025.104554_b0160","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/gene.2014.10","article-title":"Relevance of single-nucleotide polymorphisms in human TLR genes to infectious and inflammatory diseases and cancer","volume":"15","author":"Trejo-de la","year":"2014","journal-title":"Genes Immun"},{"key":"10.1016\/j.drudis.2025.104554_b0165","doi-asserted-by":"crossref","first-page":"10685","DOI":"10.1074\/jbc.M117.784470","article-title":"The R753Q polymorphism in Toll-like receptor 2 (TLR2) attenuates innate immune responses to mycobacteria and impairs MyD88 adapter recruitment to TLR2","volume":"292","author":"Pattabiraman","year":"2017","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2025.104554_b0170","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.intimp.2014.12.030","article-title":"Associations of toll-like receptor (TLR)-4 single nucleotide polymorphisms and rheumatoid arthritis disease progression: an observational cohort study","volume":"24","author":"Davis","year":"2015","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.drudis.2025.104554_b0175","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/2054431","article-title":"The interleukin-1 (IL-1) superfamily cytokines and their single nucleotide polymorphisms (SNPs)","volume":"2022","author":"Behzadi","year":"2022","journal-title":"J Immunol Res"},{"key":"10.1016\/j.drudis.2025.104554_b0180","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s10067-017-3610-0","article-title":"Association of 86 bp variable number of tandem repeat (VNTR) polymorphism of interleukin-1 receptor antagonist (IL1RN) with susceptibility and clinical activity in rheumatoid arthritis","volume":"36","author":"Ram\u00edrez-P\u00e9rez","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.drudis.2025.104554_b0185","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s10020-023-00717-3","article-title":"HMGB1 and Toll-like receptors: potential therapeutic targets in autoimmune diseases","volume":"29","author":"Ren","year":"2023","journal-title":"Mol Med"},{"key":"10.1016\/j.drudis.2025.104554_b0190","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1536258","article-title":"Editorial: gut microbiota and immunity in health and disease: dysbiosis and eubiosis\u2019s effects on the human body","volume":"15","author":"Dodero","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2025.104554_b0195","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2024.2393270","article-title":"The interplay between gut microbiota, short-chain fatty acids, and implications for host health and disease","volume":"16","author":"Hays","year":"2024","journal-title":"Gut Microbes"},{"key":"10.1016\/j.drudis.2025.104554_b0200","doi-asserted-by":"crossref","first-page":"E89","DOI":"10.1152\/ajpendo.00054.2024","article-title":"Understanding how pre- and probiotics affect the gut microbiome and metabolic health","volume":"327","author":"Bock","year":"2024","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.drudis.2025.104554_b0205","series-title":"All around Suboptimal Health: Advanced Approaches by Predictive, Preventive and Personalised Medicine for Healthy Populations","first-page":"203","article-title":"Systemic inflammation as the health-related communication tool between the human host and gut microbiota in the framework of predictive, preventive, and personalized medicine","author":"Behzadi","year":"2024"},{"key":"10.1016\/j.drudis.2025.104554_b0210","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41423-023-00987-1","article-title":"Complex regulatory effects of gut microbial short-chain fatty acids on immune tolerance and autoimmunity","volume":"20","author":"Kim","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.drudis.2025.104554_b0215","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.3389\/fmicb.2016.01296","article-title":"How rheumatoid arthritis can result from provocation of the immune system by microorganisms and viruses","volume":"7","author":"Arleevskaya","year":"2016","journal-title":"Front Microbiol"},{"key":"10.1016\/j.drudis.2025.104554_b0220","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.immuni.2011.05.006","article-title":"Toll-like receptors and their crosstalk with other innate receptors in infection and immunity","volume":"34","author":"Kawai","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.drudis.2025.104554_b0225","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature12721","article-title":"Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells","volume":"504","author":"Furusawa","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2025.104554_b0230","article-title":"Gut microbiota and rheumatoid arthritis: from pathogenesis to novel therapeutic opportunities","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2025.104554_b0235","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1136\/annrheumdis-2020-219255","article-title":"Correspondence to \u2018Bacterial citrullinated epitopes generated by Porphyromonas gingivalis infection-a missing link for ACPA production\u2019","volume":"82","author":"Ma","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.drudis.2025.104554_b0240","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1080\/08916934.2018.1527907","article-title":"Periodontal sources of citrullinated antigens and TLR agonists related to RA","volume":"51","author":"Vitkov","year":"2018","journal-title":"Autoimmunity"},{"key":"10.1016\/j.drudis.2025.104554_b0245","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","article-title":"Inflammation and tumor progression: signaling pathways and targeted intervention","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.drudis.2025.104554_b0250","doi-asserted-by":"crossref","DOI":"10.1155\/2008\/132732","article-title":"Increased responsiveness to toll-like receptor 4 stimulation in peripheral blood mononuclear cells from patients with recent onset rheumatoid arthritis","volume":"2008","author":"Kowalski","year":"2008","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.drudis.2025.104554_b0255","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1517\/14712598.2010.534080","article-title":"Modulation of toll-like receptor function has therapeutic potential in autoimmune disease","volume":"10","author":"Clanchy","year":"2010","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.drudis.2025.104554_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104372","article-title":"Multiscale modeling of innate immune receptors: endotoxin recognition and regulation by host defense peptides","volume":"147","author":"Holdbrook","year":"2019","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.drudis.2025.104554_b0265","doi-asserted-by":"crossref","first-page":"J207","DOI":"10.1016\/j.jaut.2009.12.006","article-title":"Epigenetics and autoimmunity","volume":"34","author":"Brooks","year":"2010","journal-title":"J Autoimmun"},{"key":"10.1016\/j.drudis.2025.104554_b0270","doi-asserted-by":"crossref","unstructured":"Side effects of low-dose methotrexate. Ann Intern Med. 2020;172:1\u201320. https:\/\/doi.org\/10.7326\/p20-0001.","DOI":"10.7326\/P20-0001"},{"key":"10.1016\/j.drudis.2025.104554_b0275","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/cpdd.1176","article-title":"First-in-human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of E6742, a dual antagonist of toll-like receptors 7 and 8, in healthy volunteers","volume":"12","author":"Yamakawa","year":"2023","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.drudis.2025.104554_b0280","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.immuni.2024.03.004","article-title":"Decoding Toll-like receptors: recent insights and perspectives in innate immunity","volume":"57","author":"Kawai","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.drudis.2025.104554_b0285","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nri3446","article-title":"The history of Toll-like receptors \u2013 redefining innate immunity","volume":"13","author":"O\u2019Neill","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.drudis.2025.104554_b0290","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.immuni.2017.02.006","article-title":"Immunopathogenesis of rheumatoid arthritis","volume":"46","author":"Firestein","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.drudis.2025.104554_b0295","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nrrheum.2014.85","article-title":"The eye: a window of opportunity in rheumatoid arthritis?","volume":"10","author":"Tong","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.drudis.2025.104554_b0300","doi-asserted-by":"crossref","first-page":"605","DOI":"10.15171\/apb.2015.082","article-title":"Toll-like receptors in the pathogenesis of autoimmune diseases","volume":"5","author":"Mohammad Hosseini","year":"2015","journal-title":"Adv Pharm Bull"},{"key":"10.1016\/j.drudis.2025.104554_b0305","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a011247","article-title":"Toll-like receptor signaling","volume":"5","author":"Lim","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.drudis.2025.104554_b0310","doi-asserted-by":"crossref","DOI":"10.1172\/JCI167835","article-title":"Serum amyloid A expression in liver promotes synovial macrophage activation and chronic arthritis via NFAT5","volume":"134","author":"Li","year":"2024","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2025.104554_b0315","doi-asserted-by":"crossref","first-page":"5444","DOI":"10.1038\/ncomms6444","article-title":"Fc gamma receptor-TLR cross-talk elicits pro-inflammatory cytokine production by human M2 macrophages","volume":"5","author":"Vogelpoel","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2025.104554_b0320","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/s41584-020-0413-5","article-title":"Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes","volume":"16","author":"Nygaard","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.drudis.2025.104554_b0325","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1136\/ard-2022-223396","article-title":"Cytokine-directed cellular cross-talk imprints synovial pathotypes in rheumatoid arthritis","volume":"82","author":"Kugler","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.drudis.2025.104554_b0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103120","article-title":"Significance of IL-7 and IL-7R in RA and autoimmunity","volume":"21","author":"Meyer","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.drudis.2025.104554_b0335","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrrheum.2015.169","article-title":"TNF biology, pathogenic mechanisms and emerging therapeutic strategies","volume":"12","author":"Kalliolias","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.drudis.2025.104554_b0340","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1080\/13543776.2016.1185415","article-title":"Recent progress in the development of Toll-like receptor (TLR) antagonists","volume":"26","author":"Patra","year":"2016","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.drudis.2025.104554_b0345","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1093\/rheumatology\/keaa220","article-title":"TLR1\/2 and 5 induce elevated cytokine levels from rheumatoid arthritis monocytes independent of ACPA or RF autoantibody status","volume":"59","author":"Thwaites","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.drudis.2025.104554_b0350","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/rheumatology\/ker257","article-title":"Intrinsic danger: activation of Toll-like receptors in rheumatoid arthritis","volume":"51","author":"Goh","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.drudis.2025.104554_b0355","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/clpt.2013.150","article-title":"Randomized, double-blind, placebo-controlled, dose-escalating phase I, healthy subjects study of intravenous OPN-305, a humanized anti-TLR2 antibody","volume":"94","author":"Reilly","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.drudis.2025.104554_b0360","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1007\/s12272-016-0806-9","article-title":"Toll-like receptors: promising therapeutic targets for inflammatory diseases","volume":"39","author":"Achek","year":"2016","journal-title":"Arch Pharm Res"},{"key":"10.1016\/j.drudis.2025.104554_b0365","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.bbi.2024.08.002","article-title":"TLR2 immunotherapy suppresses neuroinflammation, tau spread, and memory loss in rTg4510 mice","volume":"121","author":"Kim","year":"2024","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.drudis.2025.104554_b0370","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.autrev.2016.12.003","article-title":"TLRs, future potential therapeutic targets for RA","volume":"16","author":"Elshabrawy","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.drudis.2025.104554_b0375","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1080\/09168451.2016.1263145","article-title":"Crocin reduces the inflammation response in rheumatoid arthritis","volume":"81","author":"Li","year":"2017","journal-title":"Biosci Biotechnol Biochem"},{"key":"10.1016\/j.drudis.2025.104554_b0380","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s12026-018-8999-2","article-title":"Effects of crocin on inflammatory activities in human fibroblast-like synoviocytes and collagen-induced arthritis in mice","volume":"66","author":"Li","year":"2018","journal-title":"Immunol Res"},{"key":"10.1016\/j.drudis.2025.104554_b0385","article-title":"Natural medicines of targeted rheumatoid arthritis and its action mechanism","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2025.104554_b0390","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.829677","article-title":"The role of resveratrol on rheumatoid arthritis: from bench to bedside","volume":"13","author":"Sheng","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2025.104554_b0395","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1186\/s12967-024-05228-1","article-title":"Resveratrol attenuates inflammation and fibrosis in rheumatoid arthritis-associated interstitial lung disease via the AKT\/TMEM175 pathway","volume":"22","author":"Liu","year":"2024","journal-title":"J Transl Med"},{"key":"10.1016\/j.drudis.2025.104554_b0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114291","article-title":"Toll-like receptor 4 (TLR4) inhibitors: current research and prospective","volume":"235","author":"Zhang","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2025.104554_b0405","doi-asserted-by":"crossref","first-page":"411","DOI":"10.4049\/jimmunol.0803988","article-title":"Sulforaphane suppresses oligomerization of TLR4 in a thiol-dependent manner","volume":"184","author":"Youn","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2025.104554_b0410","doi-asserted-by":"crossref","first-page":"R220","DOI":"10.1186\/ar4059","article-title":"Sulforaphane has opposing effects on TNF-alpha stimulated and unstimulated synoviocytes","volume":"14","author":"Fragoulis","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.drudis.2025.104554_b0415","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.intimp.2010.09.020","article-title":"Inhibition of homodimerization of Toll-like receptor 4 by 4-oxo-4-(2-oxo-oxazolidin-3-yl)-but-2-enoic acid ethyl ester","volume":"11","author":"Park","year":"2011","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.drudis.2025.104554_b0420","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1136\/annrheumdis-2019-216487","article-title":"Efficacy and safety of NI-0101, an anti-Toll-like receptor 4 monoclonal antibody, in patients with rheumatoid arthritis after inadequate response to methotrexate: a phase II study","volume":"79","author":"Monnet","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.drudis.2025.104554_b0425","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/09680519000060050101","article-title":"Role of MD-2 in TLR2- and TLR4-mediated recognition of Gram-negative and Gram-positive bacteria and activation of chemokine genes","volume":"6","author":"Dziarski","year":"2000","journal-title":"J Endotoxin Res"},{"key":"10.1016\/j.drudis.2025.104554_b0430","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/s41598-017-01033-7","article-title":"Direct recognition of LPS drive TLR4 expressing CD8+T cell activation in patients with rheumatoid arthritis","volume":"7","author":"Tripathy","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2025.104554_b0435","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s00296-002-0232-9","article-title":"Effect of caffeic acid phenethyl ester on cartilage in experimental osteoarthritis","volume":"22","author":"Elmali","year":"2002","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.drudis.2025.104554_b0440","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/s12951-022-01505-7","article-title":"Arctiin-reinforced antioxidant microcarrier antagonizes osteoarthritis progression","volume":"20","author":"Liu","year":"2022","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.drudis.2025.104554_b0445","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.lfs.2019.01.002","article-title":"Nicorandil abates arthritic perturbations induced by complete Freund\u2019s adjuvant in rats via conquering TLR4-MyD88-TRAF6 signaling pathway","volume":"218","author":"Saad","year":"2019","journal-title":"Life Sci"},{"key":"10.1016\/j.drudis.2025.104554_b0450","first-page":"5002","article-title":"Astragalus polysaccharide inhibits Toll-like receptor 4\/nuclear factor kappaB p65 pathway in the treatment of knee osteoarthritis in rats","volume":"27","author":"Jingtao","year":"2023","journal-title":"Chin J Tissue Eng Res"},{"key":"10.1016\/j.drudis.2025.104554_b0455","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1136\/annrheumdis-2011-201203","article-title":"Ligation of TLR7 by rheumatoid arthritis synovial fluid single strand RNA induces transcription of TNF\u03b1 in monocytes","volume":"72","author":"Chamberlain","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.drudis.2025.104554_b0460","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1126\/science.1093616","article-title":"Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA","volume":"303","author":"Diebold","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.drudis.2025.104554_b0465","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s00296-021-05050-8","article-title":"Toll-like receptor-7 activation in CD8+ T cells modulates inflammatory mediators in patients with rheumatoid arthritis","volume":"42","author":"Swain","year":"2022","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.drudis.2025.104554_b0470","article-title":"Roles of TLR7 in activation of NF-\u03baB signaling of keratinocytes by imiquimod","volume":"8","author":"Li","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2025.104554_b0475","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2174\/187152807783334300","article-title":"TLR7\/9 antagonists as therapeutics for immune-mediated inflammatory disorders","volume":"6","author":"Sun","year":"2007","journal-title":"Inflamm Allergy Drug Targets"},{"key":"10.1016\/j.drudis.2025.104554_b0480","doi-asserted-by":"crossref","first-page":"354","DOI":"10.4103\/0253-7613.161249","article-title":"Imiquimod \u2013 its role in the treatment of cutaneous malignancies","volume":"47","author":"Bubna","year":"2015","journal-title":"Indian J Pharmacol"},{"key":"10.1016\/j.drudis.2025.104554_b0485","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s40364-022-00436-7","article-title":"Targeting Toll-like receptor 7\/8 for immunotherapy: recent advances and prospectives","volume":"10","author":"Sun","year":"2022","journal-title":"Biomark Res"},{"key":"10.1016\/j.drudis.2025.104554_b0490","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10456-015-9477-2","article-title":"The pathogenic role of angiogenesis in rheumatoid arthritis","volume":"18","author":"Elshabrawy","year":"2015","journal-title":"Angiogenesis"},{"key":"10.1016\/j.drudis.2025.104554_b0495","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jbspin.2009.05.011","article-title":"New insights in synovial angiogenesis","volume":"77","author":"Szekanecz","year":"2010","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.drudis.2025.104554_b0500","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/BOR.0b013e328337c95a","article-title":"Angiogenesis and vasculogenesis in rheumatoid arthritis","volume":"22","author":"Szekanecz","year":"2010","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.drudis.2025.104554_b0505","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vph.2009.02.002","article-title":"Angiogenesis and its targeting in rheumatoid arthritis","volume":"51","author":"Szekanecz","year":"2009","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.drudis.2025.104554_b0510","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1016\/j.apsb.2022.02.010","article-title":"Targeting macrophagic SHP2 for ameliorating osteoarthritis via TLR signaling","volume":"12","author":"Sun","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.drudis.2025.104554_b0515","doi-asserted-by":"crossref","first-page":"R33","DOI":"10.1186\/ar3261","article-title":"Blockade of Toll-like receptor 2 prevents spontaneous cytokine release from rheumatoid arthritis ex vivo synovial explant cultures","volume":"13","author":"Ultaigh","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.drudis.2025.104554_b0520","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3390\/biomedicines12010138","article-title":"Targeting TLR signaling cascades in systemic lupus erythematosus and rheumatoid arthritis: an update","volume":"12","author":"Kalliolias","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.drudis.2025.104554_b0525","doi-asserted-by":"crossref","first-page":"475","DOI":"10.4049\/jimmunol.1102977","article-title":"TLR5, a novel and unidentified inflammatory mediator in rheumatoid arthritis that correlates with disease activity score and joint TNF-\u03b1 levels","volume":"189","author":"Chamberlain","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2025.104554_b0530","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1002\/art.37992","article-title":"Angiogenesis in rheumatoid arthritis is fostered directly by Toll-like receptor 5 ligation and indirectly through interleukin-17 induction","volume":"65","author":"Kim","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.drudis.2025.104554_b0535","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrrheum.2016.178","article-title":"Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases","volume":"13","author":"Cronstein","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.drudis.2025.104554_b0540","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1161\/ATVBAHA.111.224048","article-title":"High-mobility group box-1 mediates Toll-like receptor 4-dependent angiogenesis","volume":"31","author":"Lin","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.drudis.2025.104554_b0545","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/eji.201444908","article-title":"HMGB1 induces angiogenesis in rheumatoid arthritis via HIF-1\u03b1 activation","volume":"45","author":"Park","year":"2015","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.drudis.2025.104554_b0550","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.imlet.2006.11.005","article-title":"Toll-like receptor 2 ligand mediates the upregulation of angiogenic factor, vascular endothelial growth factor and interleukin-8\/CXCL8 in human rheumatoid synovial fibroblasts","volume":"108","author":"Cho","year":"2007","journal-title":"Immunol Lett"},{"key":"10.1016\/j.drudis.2025.104554_b0555","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023540","article-title":"Toll-like receptor 2 induced angiogenesis and invasion is mediated through the Tie2 signalling pathway in rheumatoid arthritis","volume":"6","author":"Saber","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2025.104554_b0560","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/nrrheum.2015.171","article-title":"Cytokines in rheumatoid arthritis \u2013 shaping the immunological landscape","volume":"12","author":"McInnes","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.drudis.2025.104554_b0565","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrrheum.2015.157","article-title":"Successes and failures of chemokine-pathway targeting in rheumatoid arthritis","volume":"12","author":"Szekanecz","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.drudis.2025.104554_b0570","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1285455","article-title":"Immunomodulatory roles of metalloproteinases in rheumatoid arthritis","volume":"14","author":"Bian","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2025.104554_b0575","doi-asserted-by":"crossref","first-page":"6396","DOI":"10.4049\/jimmunol.0904068","article-title":"Membrane-type I matrix metalloproteinase-dependent regulation of rheumatoid arthritis synoviocyte function","volume":"184","author":"Sabeh","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2025.104554_b0580","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41584-022-00793-5","article-title":"Mechanisms of joint destruction in rheumatoid arthritis - immune cell-fibroblast-bone interactions","volume":"18","author":"Komatsu","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.drudis.2025.104554_b0585","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1136\/annrheumdis-2020-218089","article-title":"Microenvironment in subchondral bone: predominant regulator for the treatment of osteoarthritis","volume":"80","author":"Hu","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.drudis.2025.104554_b0590","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1038\/s41467-021-22454-z","article-title":"Targeted apoptosis of macrophages and osteoclasts in arthritic joints is effective against advanced inflammatory arthritis","volume":"12","author":"Deng","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2025.104554_b0595","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nrrheum.2012.153","article-title":"Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment","volume":"8","author":"Schett","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.drudis.2025.104554_b0600","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/art.10117","article-title":"How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis","volume":"46","author":"Visser","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.drudis.2025.104554_b0605","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.0105-2896.2009.00859.x","article-title":"Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis","volume":"233","author":"Bartok","year":"2010","journal-title":"Immunol Rev"},{"key":"10.1016\/j.drudis.2025.104554_b0610","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/164_2021_543","article-title":"Toll-like receptors in adaptive immunity","volume":"276","author":"Kumar","year":"2022","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.drudis.2025.104554_b0615","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1042\/CS20190728","article-title":"Skeletal muscle redox signaling in rheumatoid arthritis","volume":"134","author":"Steinz","year":"2020","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.drudis.2025.104554_b0620","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2207993120","article-title":"NOS inhibition reverses TLR2-induced chondrocyte dysfunction and attenuates age-related osteoarthritis","volume":"120","author":"Shen","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2025.104554_b0625","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s12272-010-0618-2","article-title":"TBK1-targeted suppression of TRIF-dependent signaling pathway of Toll-like receptor 3 by auranofin","volume":"33","author":"Park","year":"2010","journal-title":"Arch Pharm Res"},{"key":"10.1016\/j.drudis.2025.104554_b0630","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1126\/science.1155406","article-title":"Structural basis of Toll-like receptor 3 signaling with double-stranded RNA","volume":"320","author":"Liu","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.drudis.2025.104554_b0635","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/sj.cdd.4401850","article-title":"TLR signaling","volume":"13","author":"Kawai","year":"2006","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.drudis.2025.104554_b0640","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3389\/fimmu.2014.00461","article-title":"Toll-like receptor signaling pathways","volume":"5","author":"Kawasaki","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2025.104554_b0645","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.4049\/jimmunol.1302998","article-title":"Ligation of TLR5 promotes myeloid cell infiltration and differentiation into mature osteoclasts in rheumatoid arthritis and experimental arthritis","volume":"193","author":"Kim","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2025.104554_b0650","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.4049\/jimmunol.180.3.1382","article-title":"Stimulation by TLR5 modulates osteoclast differentiation through STAT1\/IFN-beta","volume":"180","author":"Ha","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2025.104554_b0655","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1038\/s41401-020-00578-0","article-title":"A novel tricyclic BTK inhibitor suppresses B cell responses and osteoclastic bone erosion in rheumatoid arthritis","volume":"42","author":"Liu","year":"2021","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.drudis.2025.104554_b0660","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.cell.2006.02.015","article-title":"Pathogen recognition and innate immunity","volume":"124","author":"Akira","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2025.104554_b0665","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.molmed.2007.09.002","article-title":"Signaling to NF-kappaB by Toll-like receptors","volume":"13","author":"Kawai","year":"2007","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.drudis.2025.104554_b0670","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1359\/jbmr.090533","article-title":"Osteoclasts and arthritis","volume":"24","author":"Schett","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.drudis.2025.104554_b0675","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/art.27304","article-title":"Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors","volume":"62","author":"Sacre","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.drudis.2025.104554_b0680","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.4049\/jimmunol.181.11.8002","article-title":"Inhibitors of TLR8 reduce TNF production from human rheumatoid synovial membrane cultures","volume":"181","author":"Sacre","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2025.104554_b0685","article-title":"A novel drug combination of mangiferin and cinnamic acid alleviates rheumatoid arthritis by inhibiting TLR4\/NF\u03baB\/NLRP3 activation-induced pyroptosis","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2025.104554_b0690","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.23765","article-title":"Mangiferin: a natural bioactive immunomodulating glucosylxanthone with potential against cancer and rheumatoid arthritis","volume":"38","author":"Akkewar","year":"2024","journal-title":"J Biochem Mol Toxicol"},{"key":"10.1016\/j.drudis.2025.104554_b0695","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13020-023-00863-0","article-title":"Extensive preclinical evaluation of combined mangiferin and glycyrrhizic acid for restricting synovial neovascularization in rheumatoid arthritis","volume":"18","author":"Mao","year":"2023","journal-title":"Chin Med"},{"key":"10.1016\/j.drudis.2025.104554_b0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108352","article-title":"Mangiferin exert protective effects on joints of adjuvant-induced arthritis rats by regulating the MAPKs\/NF-\u03baB pathway of fibroblast-like synoviocytes","volume":"101","author":"Wang","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.drudis.2025.104554_b0705","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1073\/pnas.0400525101","article-title":"Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection","volume":"101","author":"Tabeta","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2025.104554_b0710","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1084\/jem.20030162","article-title":"Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells","volume":"198","author":"Lund","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.drudis.2025.104554_b0715","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/ni1479","article-title":"Ligand-induced conformational changes allosterically activate Toll-like receptor 9","volume":"8","author":"Latz","year":"2007","journal-title":"Nat Immunol"},{"key":"10.1016\/j.drudis.2025.104554_b0720","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nrd2059","article-title":"Therapeutic potential of Toll-like receptor 9 activation","volume":"5","author":"Krieg","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2025.104554_b0725","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1600-065X.2007.00572.x","article-title":"Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity","volume":"220","author":"Krieg","year":"2007","journal-title":"Immunol Rev"},{"key":"10.1016\/j.drudis.2025.104554_b0730","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12016-010-8243-x","article-title":"Hydroxychloroquine: from malaria to autoimmunity","volume":"42","author":"Ben-Zvi","year":"2012","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.drudis.2025.104554_b0735","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.182.Supp.48.25","article-title":"IMO-3100, an antagonist of Toll-like receptors 7 and 9, modulates gene expression and regulatory networks induced by ligands (48.25)","volume":"182","author":"Jiang","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2025.104554_b0740","doi-asserted-by":"crossref","first-page":"726","DOI":"10.2119\/molmed.2015.00154","article-title":"Simvastatin inhibits Toll-like receptor 8 (TLR8) signaling in primary human monocytes and spontaneous tumor necrosis factor production from rheumatoid synovial membrane cultures","volume":"21","author":"Mullen","year":"2015","journal-title":"Mol Med"},{"key":"10.1016\/j.drudis.2025.104554_b0745","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/nchembio.2518","article-title":"Small-molecule inhibition of TLR8 through stabilization of its resting state","volume":"14","author":"Zhang","year":"2018","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.drudis.2025.104554_b0750","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1126\/science.1229159","article-title":"Structural reorganization of the Toll-like receptor 8 dimer induced by agonistic ligands","volume":"339","author":"Tanji","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.drudis.2025.104554_b0755","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103189","article-title":"Extracellular microRNAs induce dendritic cell-dependent joint inflammation and potentiate osteoclast differentiation via TLR7\/8 engagement","volume":"145","author":"Gaudenzi","year":"2024","journal-title":"J Autoimmun"},{"key":"10.1016\/j.drudis.2025.104554_b0760","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s10616-012-9442-5","article-title":"R848, a Toll-like receptor 7 agonist, inhibits osteoclast differentiation but not survival or bone-resorbing function of mature osteoclasts","volume":"64","author":"Miyamoto","year":"2012","journal-title":"Cytotechnology"},{"key":"10.1016\/j.drudis.2025.104554_b0765","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/art.39544","article-title":"Identification of a novel Toll-like receptor 7 endogenous ligand in rheumatoid arthritis synovial fluid that can provoke arthritic joint inflammation","volume":"68","author":"Kim","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.drudis.2025.104554_b0770","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s11095-007-9428-8","article-title":"Influence of plasma cholesterol and triglyceride concentrations and eritoran (E5564) micelle size on its plasma pharmacokinetics and ex vivo activity following single intravenous bolus dose into healthy female rabbits","volume":"25","author":"Wasan","year":"2008","journal-title":"Pharm Res"},{"key":"10.1016\/j.drudis.2025.104554_b0775","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0099053","article-title":"Toll-like receptor 4 mediates endothelial cell activation through NF-\u03baB but is not associated with endothelial dysfunction in patients with rheumatoid arthritis","volume":"9","author":"Menghini","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2025.104554_b0780","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13075-020-2097-2","article-title":"Investigation of Toll-like receptor (TLR) 4 inhibitor TAK-242 as a new potential anti-rheumatoid arthritis drug","volume":"22","author":"Samarpita","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.drudis.2025.104554_b0785","first-page":"453","article-title":"Evaluation of TAK-242 (resatorvid) effects on inflammatory status of fibroblast-like synoviocytes in rheumatoid arthritis and trauma patients","volume":"20","author":"Karami","year":"2021","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"10.1016\/j.drudis.2025.104554_b0790","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jaad.2023.02.072","article-title":"Drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms. Part I. Epidemiology, pathogenesis, clinicopathological features, and prognosis","volume":"90","author":"Wei","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.drudis.2025.104554_b0795","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/s41591-019-0733-7","article-title":"Targeted therapy guided by single-cell transcriptomic analysis in drug-induced hypersensitivity syndrome: a case report","volume":"26","author":"Kim","year":"2020","journal-title":"Nat Med"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625002673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625002673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T16:04:24Z","timestamp":1778601864000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644625002673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":159,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1359644625002673"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104554","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances and challenges in Toll-like receptor-targeted therapy for rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104554","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104554"}}